Success Stories: NIW Approved for a Taiwanese Postdoctoral Researcher Revolutionizing Liver Disease Research
Client’s Testimonial:
“Working with Chen Immigration on my NIW petition was an excellent decision. Their team demonstrated deep expertise, crafted a compelling case highlighting my qualifications and national interest contributions, and guided me through each step with clarity and professionalism. Thanks to their efforts, my NIW was approved without a Request for Evidence (RFE).”
On May 13th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Taiwan
State of Residence at the Time of Filing: California
Approval Notice Date: May 13th, 2025
Processing Time: 2 months (Premium Processing Requested)
Case Summary:
We are delighted to share the successful outcome of a National Interest Waiver (NIW) petition for a highly accomplished postdoctoral researcher from Taiwan. With cutting-edge research in stem cell modeling and genome editing, the client’s work focuses on identifying molecular drivers of liver disease using the CRISPR-Cas9 system in patient-derived induced pluripotent stem cells (iPSCs). Her proposed endeavor addresses the national public health challenge posed by liver disorders, including metabolic dysfunction-associated fatty liver disease (MAFLD) and liver cancer, offering innovative avenues for therapeutic discovery.
Driving Innovation in Liver Disease Research
Our client is currently engaged in research at a leading U.S. medical institution, where she leverages advanced cellular models and gene-editing technologies to uncover molecular mechanisms underlying chronic liver conditions. Her goal is to identify critical targets that could be used to develop effective therapies, reduce healthcare burdens, and improve the quality of life for patients suffering from liver-related diseases. With MAFLD affecting approximately 100 million Americans, her work directly aligns with national biomedical priorities and public health objectives.
Accomplishments That Establish Her Significance
We substantiated our client’s qualifications by highlighting her measurable research impact: - 266 total citations to her published work, including three papers ranked among the top 10% most cited for their respective years. - 11 peer-reviewed journal articles, including 6 first- or co-first-authored papers, and 2 first-authored abstracts, published in top-tier journals such as Biomedicine & Pharmacotherapy, Scientific Reports, and Phytomedicine. - 8 completed peer reviews for leading scientific journals, underscoring her expertise and peer recognition in molecular biology.
Her articles have been referenced in diverse studies ranging from molecular cancer mechanisms to drug resistance strategies, reflecting her influence on international research across multiple disciplines.
Strategic Emphasis on National Relevance
In building the petition, we emphasized the national importance of the client’s proposed endeavor, particularly its potential to impact biotechnology innovation, therapeutic development, and U.S. leadership in critical and emerging technologies. Her work supports the advancement of biotechnologies and genome editing—domains identified as essential by the National Science and Technology Council—and addresses the clinical and economic burdens of liver disease through novel research strategies.
A Swift Approval Validating Exceptional Merit
Given the strength of her petition, which featured robust evidence of scientific merit, field impact, and national benefit, USCIS approved the case just two months after filing with premium processing. This quick turnaround illustrates both the thoroughness of our case preparation and the clear alignment between the client’s work and U.S. national interest objectives.
We are proud to have represented this outstanding researcher and celebrate her continued contributions to advancing therapeutic research and public health in the United States.